Recently, NAT regimens comprising dual-target drugs, such as the combinations of trastuzumab plus pertuzumab (NeoSphere and PEONY) and trastuzumab plus small molecule tyrosine kinase inhibitor (NeoALLTO), have been extensively utilized in HER2-positive BC management due to their superior effects (almost twice the pCR rate) compared with single-target therapies (4–6). This evidence concerns the gene ERBB2 and breast cancer.